Latest Immunosuppressants Stories
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
SAN FRANCISCO, Dec.
- Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia EAST HANOVER, N.J., Dec.
DALLAS, December 1, 2014 /PRNewswire/ -- ReportsnReports.com adds EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023 market research on the autoimmune
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.
However, Platform Injectables Continue to Represent the Majority of Recent MS Prescriptions, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
U.S. Court of Appeals for the Federal Circuit Concurrently Affirms Denial of Antares Pharma's Motion to Prohibit the Marketing of Rasuvo CHICAGO, Nov.
Right the Wrong Campaign seeks to educate Canadians on how a government approved drug left them with severe birth defects that challenge their lives to this day MONTREAL, Nov.
- A person in a secondary role, specifically the second most important character (after the protagonist).